Kenneth Leung, MD
Pulmonary Disease · Ashland, KYNPI 1518306471
Payments from drug & device makers
Across 387 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Actelion Pharmaceuticals US, Inc.$948
- United Therapeutics Corporation$597
- Novartis$503
- Boehringer Ingelheim$493
- AstraZeneca$411
- plus $2K from 23 others
What the payments were for
- Food & beverage$8,25999%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 174 | $3,212 |
| Actelion Pharmaceuticals US, Inc. | 33 | $948 |
| United Therapeutics Corporation | 14 | $597 |
| Novartis | 24 | $503 |
| Boehringer Ingelheim | 25 | $493 |
| AstraZeneca | 19 | $411 |
| Sanofi | 11 | $309 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $296 |
| Genentech USA, Inc. | 18 | $285 |
| Abbott | 2 | $170 |
| Merck | 3 | $156 |
| Mylan Specialty L.p. | 6 | $130 |
| Johnson & Johnson | 8 | $124 |
| Amgen | 2 | $109 |
| CSL Behring | 4 | $107 |
| Pulmonx Corporation | 3 | $97 |
| Electromed, Inc. | 7 | $57 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Medical Graphics Corporation | 1 | $34 |
| Circassia Inc. | 2 | $28 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Viatris Specialty LLC | 1 | $25 |
| Philips North America LLC | 1 | $25 |
| Stryker | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$265
- OPSUMIT$265
- CardioMEMS HF System$147
- TYVASO$125
- TRELEGY ELLIPTA$121
How this compares
$8,336 in reported general payments places this provider in the 65th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 58 | $725,194 |
| UptraviSelexipag | 11 | $379,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $149,495 |
| Tadalafil | 41 | $75,303 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $53,105 |
| AdcircaTadalafil | 12 | $49,358 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $42,167 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $22,842 |
| Spiriva RespimatTiotropium Bromide | 21 | $21,815 |
| Spiriva HandihalerTiotropium Bromide | 21 | $16,352 |
| EliquisApixaban | 17 | $14,288 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $12,421 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $10,450 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,499 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $948 | $1,104,68969 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $3,212 | $213,050231 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $411 | $54,58880 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $493 | $51,15661 claims |
| United Therapeutics CorporationAdcirca | $597 | $49,35812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Ashland
- Sana GhalibAshland$16K
- Sabrina RobertsAshland$15K
- Scott NelsonAshland$12K
- Mena ShehataAshland$11K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.